Topical Imiquimod in Treating Patients With Recurrent Paget's Disease of the Vulva
This trial is active, not recruiting.
|Treatments||imiquimod, biopsy, therapeutic conventional surgery|
|Sponsor||Memorial Sloan Kettering Cancer Center|
|Collaborator||National Cancer Institute (NCI)|
|Start date||April 2007|
|End date||April 2017|
|Trial size||8 participants|
|Trial identifier||NCT00504023, 07-029, MSKCC-07029|
RATIONALE: Biological therapies, such as imiquimod, may stimulate the immune system in different ways and stop tumor cells from growing. Applying topical imiquimod to the vulva may be an effective treatment for recurrent Paget's disease.
PURPOSE: This clinical trial is studying how well topical imiquimod works in treating patients with recurrent Paget's disease of the vulva.
|United States||No locations recruiting|
|Other countries||No locations recruiting|
|New York, NY||Memorial Sloan Kettering Cancer Center||no longer recruiting|
|Columbus, OH||Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center||no longer recruiting|
|Endpoint classification||safety/efficacy study|
|Intervention model||single group assignment|
Clinical and histologic effects
time frame: 2 years
Female participants at least 18 years old.
- Age ≥18.
- Ability to give informed consent.
- Patients must have biopsy proven recurrent extramammary Paget's disease confirmed at the participating site.
- Patients with known hypersensitivity to imiquimod.
- Pregnant and nursing women are not eligible
- Patients with underlying adenocarcinoma on biopsy of lesion confirmed at the participating site.
|Official title||A Pilot Study of Topical Imiquimod Therapy for the Treatment of Recurrent Extramammary Paget's Disease|
|Principal investigator||Dennis S. Chi, MD, FACOG, FACS|
|Description||OBJECTIVES: - To assess the clinical and histologic effects of topical imiquimod therapy on recurrent extramammary Paget's disease. OUTLINE: This is a pilot, prospective, multicenter study. Patients apply topical imiquimod cream to a target vulvar lesion 3 times weekly. Treatment continues for up to 12 weeks in the absence of disease progression or unacceptable toxicity. If the lesion is still present after completion of 12 weeks of imiquimod therapy, the patient undergoes surgical excision of the target lesion (and any other progressive lesions suspicious for evolving adenocarcinoma) at week 16. Patients undergo punch biopsy and photographic assessment of a target vulvar lesion at baseline and again at 12 weeks. After completion of imiquimod therapy or after surgical excision, patients are followed at 6 weeks and then every 3 months for at least 2 years.|
Call for more information